Against the price increases of pharmaceutical companies, 250 hospitals in the USA have started to produce the drugs themselves

In the United States hospitals are making a common front against the big pharmaceutical companies, trying to solve the problems related to the shortage and the prices of the most used generic drugs . This is why more and more facilities are joining a non-profit society that aims to create some of these drugs on their own. The goal is to produce at least 14 types of injectable solutions most used in hospitals by the end of 2019 .

 Photo Source | Pixnio 

Against the price increases of pharmaceutical companies, 250 hospitals in the USA have started to produce the drugs themselves It is called Civica Rx the idea that American hospitals have had to face the shortcomings and price increases of medicines produced by large pharmaceutical companies. 

This is a non-profit making company which has now joined more than 250 hospitals since it was announced in early 2018 . This important initiative has garnered great support also in Catholic hospitals, and seems to have aroused interest and help from the government. 

As CEO of this company, an old acquaintance in the two-year-old sector has been named: Martin VanTrieste at the time an important member of pharmaceutical companies such as Bayer and Abbott . Just to witness the revolutionary intent of this project, the man decided that the compensation received will be entirely donated to cover other expenses of the company.

 Photo Source | Pixnio

For the moment, Civica will start the production of 14 injectable generic drugs whose distribution is expected by 2019. Of course, it is essential that these drugs are indispensable and lacking in hospitals, and those that are dated with prohibitive prices due to virtually no production competition.

The commercial choices of the big pharmaceutical companies have had a great influence on the current status of the stocks of medicines.  In some cases, drugs that have become discontinued and others produced by a single supplier have meant a considerable increase in prices, even for simple, commonly used antibiotics and saline solutions. We therefore have to wait to see what kind of impact this interesting initiative will have and what will be the response from pharmaceutical companies.

Source — Businessinsider | Nytimes